Identification of novel mycocompounds as inhibitors of PI3K/AKT/mTOR pathway against RCC

References

• Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3(1):1–19.
   Google Scholar
• Shinder BM, Rhee K, Farrell D, et al. Surgical management of advanced and metastatic renal cell carcinoma: a multidisciplinary approach. Front Oncol. 2017;7:107.
   PubMed Web of Science ®Google Scholar
• Tang T, Du X, Zhang X, et al. Computational identification and analysis of early diagnostic biomarkers for kidney cancer. J Hum Genet. 2019;64(10):1015–1022.
   PubMed Web of Science ®Google Scholar
• Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin. 2017;67(6):507–524.
   PubMed Web of Science ®Google Scholar
• Posadas EM, Limvorasak S, Figlin RA. Targeted therapies for renal cell carcinoma. Nat Rev Nephrol. 2017;13(8):496–511.
   PubMed Web of Science ®Google Scholar
• Markman B, Dienstmann R, Tabernero J. Targeting the PI3K/Akt/mTOR pathway–beyond rapalogs. Oncotarget. 2010;1(7):530–543.
   PubMedGoogle Scholar
• Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 2014;4:64.
   PubMedGoogle Scholar
• Ye X, Ruan J-W, Huang H, et al. PI3K-Akt-mTOR inhibition by GNE-477 inhibits renal cell carcinoma cell growth in vitro and in vivo. Aging (Albany NY). 2020;12(10):9489–9499.
   PubMedGoogle Scholar
• Venturella G, Ferraro V, Cirlincione F, et al. Medicinal mushrooms: bioactive compounds, use, and clinical trials. IJMS. 2021;22(2):634.
   Google Scholar
• Pavithra M, Sridhar KR, Greeshma AA, et al. Bioactive potential of the wild mushroom astraeus hygrometricus in South-west India. Mycology. 2016;7(4):191–202.
   PubMedGoogle Scholar
• Sánchez C. Bioactives from mushroom and their application. In Food bioactives. Cham: Springer; 2017. p. 23–57.
   Google Scholar
• Biswas G, Nandi S, Kuila D, et al. A comprehensive review on food and medicinal prospects of astraeus hygrometricus. PJ. 2017;9(6):799–806.
   Google Scholar
• Biswas G, Sarkar S, Acharya K. Hepatoprotective activity of the ethanolic extract of astraeus hygrometricus (Pers.) Morg. Dig J Nanomater Bios. 2011;6(2):637–641.
   Web of Science ®Google Scholar
• Mallick S, Dutta A, Dey S, et al. Selective inhibition of Leishmania donovani by active extracts of wild mushrooms used by the tribal population of India: an in vitro exploration for new leads against parasitic protozoans. Exp Parasitol. 2014;138:9–17.
   PubMed Web of Science ®Google Scholar
• Subrata G, Gunjan B, Prakash P, et al. Antimicrobial activities of basidiocarps of wild edible mushrooms of West Bengal, India. Int J PharmTech Res. 2012;4(4):1554–1560.
   Google Scholar
• Rai M, Sen S, Acharya K. Antimicrobial activity of four wild edible mushrooms from darjeeling hills, West Bengal, India. Int J PharmTech Res. 2013;5(3):949–956.
   Google Scholar
• Biswas G, Chatterjee S, Acharya K. Chemopreventive activity of the ethanolic extract of astraeus hygrometricus (Pers.) Morg. on Ehrlich’s ascites carcinoma cells. Digest J Nanomater Biostruct. 2012;7(1):185–191.
   Web of Science ®Google Scholar
• Biswas G, Acharya K. Hypoglycemic activity of ethanolic extract of astraeus hygrometricus (Pers.) Morg. in alloxan-induced diabetic mice. Int J Pharm Pharm Sci. 2013;5(1):391–394.
   Google Scholar
• Xu D, Zhang Y. Improving the physical realism and structural accuracy of protein models by a two-step atomic-level energy minimization. Biophys J. 2011;101(10):2525–2534.
   PubMed Web of Science ®Google Scholar
• Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. In: Chemical biology. Springer Berlin, Heidelberg, Germany: Springer; 2015. p. 243–250.
   Google Scholar
• Arora S, Lohiya G, Moharir K, et al. Identification of potential flavonoid inhibitors of the SARS-CoV-2 main protease 6YNQ: a molecular docking study. Digital Chin Med. 2020;3(4):239–248.
   Google Scholar
• Vardhan S, Sahoo S. In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19. Comput Biol Med. 2020;124:103936.
   PubMed Web of Science ®Google Scholar
• Shah S, Chaple D, Arora S, et al. Exploring the active constituents of oroxylum indicum in intervention of novel coronavirus (COVID-19) based on molecular docking method. Netw Model Anal Health Inform Bioinform. 2021;10(1):1–12.
   Web of Science ®Google Scholar
• Lagunin A, Zakharov A, Filimonov D, et al. QSAR modelling of rat acute toxicity on the basis of PASS prediction. Mol Inform. 2011;30(2-3):241–250.
   PubMed Web of Science ®Google Scholar
• Ivanov SM, Lagunin AA, Rudik AV, et al. ADVERPred–web service for prediction of adverse effects of drugs. J Chem Inf Model. 2018;58(1):8–11.
   PubMed Web of Science ®Google Scholar
• Lagunin A, Rudik A, Druzhilovsky D, et al. ROSC-Pred: web-service for rodent organ-specific carcinogenicity prediction. Bioinformatics. 2018;34(4):710–712.
   PubMed Web of Science ®Google Scholar
• Cadow J, Born J, Manica M, et al. PaccMann: a web service for interpretable anticancer compound sensitivity prediction. Nucleic Acids Res. 2020;48(W1):W502–W508.
   PubMed Web of Science ®Google Scholar
• Poroikov VV, Filimonov DA, Ihlenfeldt W-D, et al. PASS biological activity spectrum predictions in the enhanced open NCI database browser. J Chem Inf Comput Sci. 2003;43(1):228–236.
   PubMedGoogle Scholar
• Pires DE, Blundell TL, Ascher DB. pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem. 2015;58(9):4066–4072.
   PubMed Web of Science ®Google Scholar
• Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7(1):42713–42717.
   PubMedGoogle Scholar
• Rehan M, Bajouh OS. Virtual screening of naphthoquinone analogs for potent inhibitors against the cancer‐signaling PI3K/AKT/mTOR pathway. J Cell Biochem. 2019;120(2):1328–1339.
   PubMed Web of Science ®Google Scholar
• Umar AK. Flavonoid compounds of buah merah (Pandanus conoideus lamk) AS A potent SARS-cov-2 main protease inhibitor: in silico approach. Futur J Pharm Sci. 2021;7(1):158.doi:10.1186/s43094-021-00309-0. PMC: 34395638
   PubMed Web of Science ®Google Scholar
• Klümper N, Blajan I, Schmidt D, et al. Downstream neighbor of SON (DONSON) is associated with unfavorable survival across diverse cancers with oncogenic properties in clear cell renal cell carcinoma. Transl Oncol. 2020;13(11):100844.
   PubMed Web of Science ®Google Scholar
• Ruan H, Yang H, Wei H, et al. Overexpression of SOX4 promotes cell migration and invasion of renal cell carcinoma by inducing epithelial-mesenchymal transition. Int J Oncol. 2017;51(1):336–346.
   PubMed Web of Science ®Google Scholar
• Li H, Qu L, Zhou R, et al. TRIM13 inhibits cell migration and invasion in clear-cell renal cell carcinoma. Nutr Cancer. 2020;72(7):1115–1124.
   PubMed Web of Science ®Google Scholar
• Kim HD, Yu S-J, Kim HS, et al. Interleukin-4 induces senescence in human renal carcinoma cell lines through STAT6 and p38 MAPK. J Biol Chem. 2013;288(40):28743–28754.
   PubMed Web of Science ®Google Scholar
• Wang W, Zhou PH, Hu W. Overexpression of FOXO4 induces apoptosis of clear-cell renal carcinoma cells through downregulation of Bim. Mol Med Rep. 2016;13(3):2229–2234.
   PubMed Web of Science ®Google Scholar
• Yi Y, Zhou Y, Chu X, et al. Blockade of adenosine A2b receptor reduces tumour growth and migration in renal cell carcinoma. J Cancer. 2020;11(2):421–431.
   PubMed Web of Science ®Google Scholar
• Meng J, Gao L, Zhang M, et al. Systematic investigation of the prognostic value of cell division cycle-associated proteins for clear cell renal cell carcinoma patients. Biomark Med. 2020;14(3):223–238.
   PubMed Web of Science ®Google Scholar
• Campbell CE, Kuriyan NP, Rackley RR, et al. Constitutive expression of the wilms tumor suppressor gene (WT1) in renal cell carcinoma. Int J Cancer. 1998;78(2):182–188. doi:10.1002/(SICI)1097-0215(19981005)78:2<182::AID-IJC11>3.0.CO;2-D.
   PubMed Web of Science ®Google Scholar
• Yang F-Q, Zhang J-Q, Jin J-J, et al. HOXA11-AS promotes the growth and invasion of renal cancer by sponging mir-146b-5p to upregulate MMP16 expression. J Cell Physiol. 2018;233(12):9611–9619. doi:10.1002/jcp.26864.
   PubMed Web of Science ®Google Scholar
• Heusschen R, Schulkens IA, Van Beijnum J, et al. Endothelial LGALS9 splice variant expression in endothelial cell biology and angiogenesis. Biochim Biophys Acta. 2014;1842(2):284–292. doi:10.1016/j.bbadis.2013.12.003.
   PubMed Web of Science ®Google Scholar
• Sarto C, Valsecchi C, Magni F, et al. Expression of heat shock protein 27 in human renal cell carcinoma. Proteomics. 2004;4(8):2252–2260. doi:10.1002/pmic.200300797.
   PubMed Web of Science ®Google Scholar
• Nakanishi H, Miyata Y, Mochizuki Y, et al. Pathological significance and prognostic roles of densities of CD57+ cells, CD68+ cells, and mast cells, and their ratios in clear cell renal cell carcinoma. Hum. Pathol. 2018;79:102–108. doi:10.1016/j.humpath.2018.05.007.
   PubMed Web of Science ®Google Scholar
• Du R, Huang C, Liu K, et al. Targeting AURKA in cancer: molecular mechanisms and opportunities for cancer therapy. Mol Cancer. 2021;20(1):15.doi:10.1186/s12943-020-01305-3. PMC: 33451333
   PubMed Web of Science ®Google Scholar
• Xu H, Li W, Qi K, et al. A novel function of NUCB2 in promoting the development and invasion of renal cell carcinoma. Oncol Lett. 2018;15(2):2425–2430. doi:10.3892/ol.2017.7563. 29434954
   PubMed Web of Science ®Google Scholar
• Yin L, Li W, Xu A, et al. SH3BGRL2 inhibits growth and metastasis in clear cell renal cell carcinoma via activating hippo/TEAD1-Twist1 pathway. EBioMedicine. 2020;51:102596.doi:10.1016/j.ebiom.2019.12.005. PMC: 31911271
   PubMed Web of Science ®Google Scholar
• Huang Z, Hua Y, Tian Y, et al. High expression of fructose-bisphosphate aldolase�a induces progression of renal cell carcinoma. Oncol Rep. 2018; doi:10.3892/or.2018.6378.
   Web of Science ®Google Scholar
• Dasgupta A, Dey D, Ghosh D, et al. Astrakurkurone, a sesquiterpenoid from wild edible mushroom, targets liver cancer cells by modulating bcl‐2 family proteins. IUBMB Life. 2019;71(7):992–1002.
   PubMed Web of Science ®Google Scholar
• Rodriguez S, Skeet K, Mehmetoglu-Gurbuz T, et al. Phytochemicals as an alternative or integrative option, in conjunction with conventional treatments for hepatocellular carcinoma. Cancers. 2021;13(22):5753.
   PubMed Web of Science ®Google Scholar
• Zhao Y-Y, Shen X, Chao X, et al. Ergosta-4, 6, 8 (14), 22-tetraen-3-one induces G2/M cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells. Biochim Biophys Acta. 2011;1810(4):384–390.
   PubMed Web of Science ®Google Scholar
• Cragg GM, Pezzuto J. Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents. Med Princ Pract. 2016;25(Suppl. 2):41–59.
   PubMedGoogle Scholar
• Panda SK, Sahoo G, Swain SS, et al. Anticancer activities of mushrooms: a neglected source for drug discovery. Pharmaceuticals. 2022;15(2):176.
   Web of Science ®Google Scholar
• Aggarwal S, John S, Sapra L, et al. Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells. Cancer Chemother Pharmacol. 2019;83(3):451–461.
   PubMed Web of Science ®Google Scholar
• Damayanti NP, Budka JA, Khella HW, et al. Therapeutic targeting of TFE3/IRS-1/PI3K/mTOR axis in translocation renal cell CarcinomaTFE3 translocation renal cell carcinoma and PI3K/mTOR. Clin Cancer Res. 2018;24(23):5977–5989.
   PubMed Web of Science ®Google Scholar
• Pal SK, Quinn DI. Differentiating mTOR inhibitors in renal cell carcinoma. Cancer Treat Rev. 2013;39(7):709–719.
   PubMed Web of Science ®Google Scholar
• Shah FH, Kim S. Identification of medicinal compounds as potential inhibitors for mutated isocitrate dehydrogenases against chondrosarcoma. Saudi J Biol Sci. 2022;29(1):161–167.
   PubMed Web of Science ®Google Scholar